FNV vs. BIB
FNV (Franco-Nevada Corporation) is a stock, while BIB (ProShares Ultra Nasdaq Biotechnology) is Leveraged Equities fund tracking the NASDAQ Biotechnology Index (200%). Over the past 10 years, FNV returned 12.65%/yr vs 9.71%/yr for BIB. At a 0.15 correlation, their price movements are largely independent.
Performance
FNV vs. BIB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, FNV achieves a 3.59% return, which is significantly lower than BIB's 12.50% return. Over the past 10 years, FNV has outperformed BIB with an annualized return of 12.65%, while BIB has yielded a comparatively lower 9.71% annualized return.
FNV
- 1D
- -3.09%
- 1M
- -5.22%
- YTD
- 3.59%
- 6M
- -0.52%
- 1Y
- 28.87%
- 3Y*
- 16.58%
- 5Y*
- 9.10%
- 10Y*
- 12.65%
BIB
- 1D
- 1.97%
- 1M
- 9.49%
- YTD
- 12.50%
- 6M
- 8.62%
- 1Y
- 100.86%
- 3Y*
- 19.65%
- 5Y*
- -0.74%
- 10Y*
- 9.71%
FNV vs. BIB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
FNV Franco-Nevada Corporation | 3.59% | 77.81% | 7.41% | -17.96% | -0.39% | 11.57% | 22.31% | 48.92% | -11.00% | 35.45% |
BIB ProShares Ultra Nasdaq Biotechnology | 12.50% | 59.21% | -9.84% | -1.06% | -28.85% | -6.02% | 39.79% | 46.71% | -24.93% | 40.49% |
Correlation
The correlation between FNV and BIB is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.24 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since Apr 8, 2010 | 0.15 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
FNV vs. BIB — Risk / Return Rank
FNV
BIB
FNV vs. BIB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Franco-Nevada Corporation (FNV) and ProShares Ultra Nasdaq Biotechnology (BIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FNV | BIB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.72 | ||
| Sortino ratioReturn per unit of downside risk | -1.88 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.36 | -0.20 |
| Calmar ratioReturn relative to maximum drawdown | 1.13 | 5.99 | -4.86 |
| Martin ratioReturn relative to average drawdown | 2.72 | 18.30 | -15.58 |
Loading charts...
Drawdowns
FNV vs. BIB - Drawdown Comparison
The maximum FNV drawdown since its inception was -58.76%, smaller than the maximum BIB drawdown of -67.24%. Use the drawdown chart below to compare losses from any high point for FNV and BIB.
Loading charts...
Drawdown Indicators
| FNV | BIB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -58.76% | -67.24% | +8.48% |
Max Drawdown (1Y)Largest decline over 1 year | -25.68% | -16.92% | -8.76% |
Max Drawdown (3Y)Largest decline over 3 years | -29.64% | -45.30% | +15.66% |
Max Drawdown (5Y)Largest decline over 5 years | -37.12% | -65.86% | +28.74% |
Max Drawdown (10Y)Largest decline over 10 years | -37.12% | -66.20% | +29.08% |
Current DrawdownCurrent decline from peak | -23.54% | -17.29% | -6.25% |
Average DrawdownAverage peak-to-trough decline | -13.98% | -32.71% | +18.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.67% | 5.53% | +5.14% |
Volatility
FNV vs. BIB - Volatility Comparison
Franco-Nevada Corporation (FNV) and ProShares Ultra Nasdaq Biotechnology (BIB) have volatilities of 13.78% and 13.56%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| FNV | BIB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.78% | 13.56% | +0.22% |
Volatility (6M)Calculated over the trailing 6-month period | 30.94% | 31.65% | -0.71% |
Volatility (1Y)Calculated over the trailing 1-year period | 36.78% | 40.43% | -3.65% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 30.54% | 43.60% | -13.06% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 30.22% | 46.39% | -16.17% |
Dividends
FNV vs. BIB - Dividend Comparison
FNV's dividend yield for the trailing twelve months is around 0.77%, more than BIB's 0.55% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.55% | 0.77% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
FNV Franco-Nevada Corporation | 0.77% | 0.73% | 1.22% | 1.23% | 0.94% | 1.10% | 0.82% | 0.96% | 1.35% | 1.14% | 1.46% | 1.81% |
Frequently Asked Questions
FNV and BIB have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
FNV has higher volatility (13.78%) compared to BIB (13.56%). In terms of maximum drawdown, FNV dropped -58.76% vs BIB's -67.24%.
BIB currently has the higher Sharpe Ratio (2.51 vs 0.79), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for FNV and BIB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer